Insulin resistance implications for type II diabetes mellitus and coronary heart disease

American Journal of Medicine

Volumn 103, Issue 2, 1997, Pages 152-162

  Haffner, Steven M ^a   Miettinen, Heikki ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; INSULIN; METFORMIN; THIAZIDE DIURETIC AGENT; TROGLITAZONE;

GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MEXICAN AMERICANS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030754126     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00027-2     Document Type: Review

References (106)

1. DeFronzo RA. Lilly Lecture 1987: The triumvirate: β-cell, muscle, liver: a collusion responsible for type II diabetes. Diabetes. 1988;37:667-687.
2. Reaven GM. 1988 Banting Lecture: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
3. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analyses of the insulin resistance syndrome (Syndrome X). Diabetes. 1992;41:715-722.
4. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
5. Haffner SM, Bowsher RR, Mykkänen L, Hazuda HP, Mitchell BD, Valdez RA, Gingerich R, Monterossa A, Stern MP. Proinsulin and specific insulin concentrations in high and low risk populations for type II diabetes. Diabetes. 1994;43:1490-1493.
6. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven GM. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. NEJM. 1989;320:702-706.
7. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. NEJM. 1987;317:350-357.
8. DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
9. Haffner SM. Editorial: Insulin and blood pressure: fact or fantasy? J Clin Endocrinol Metab. 1993;76:541-543.
10. Laakso M, Sarlund H, Mykkänen L. Essential hypertension and insulin resistance in non-insulin dependent diabetes. Eur J Clin Invest. 1989;19:518-526.
11. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, DeGregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV, Bogardus C. Racial differences in the relation between blood pressure and insulin resistance. NEJM. 1991;324:733-739.
12. Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension. 1990;16:706-711.
13. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension. 1992;20:38-45.
14. Laws A, King AC, Haskell WL, Reaven GM. Relation of fasting plasma insulin concentrations to high density lipoprotein cholesterol and triglyceride concentrations in men. Arterioscler Thromb. 1991;11:1636-1642.
15. Garg A, Helderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metabolism. 1988;37:982-987.
16. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
17. Reaven GM, Chen YDI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small dense, low density lipoprotein particles. J Clin Invest. 1993;92:141-146.
18. Haffner SM, Mykkänen L, Paidi M, Valdez R, Howard BV, Stern MP. Small dense LDL is associated with the insulin resistance syndrome. Diabetologia. 1995;38:1328-1336.
19. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matloff J, Morgenstern L, Ganz W, Swan HJC, Forrester J. Coronary angioscopy in patients with unstable angina pectoris. NEJM. 1986;315:913-919.
20. Hamsten A, Wiman B, DeFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. NEJM. 1985;313:1557-1563.
21. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
22. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
23. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
24. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population: sixteen-year follow-up. Diabetes. 1974;23:105-111.
25. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
26. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713-1724.
27. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: the World Health Organization Multinational Study of vascular disease in diabetics. Diabetologia. 1985;28:615-640.
28. Klein R, Klein BEK, Moss SE, Davis MD, De Mets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864-2871.
29. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: The Whitehall Study. Lancet. 1980;1:1373-1376.
30. Jarrett RJ. Type II (non-insulin-dependent) diabetes mellitus and coronary heart disease - chicken, egg, or neither? Diabetologia. 1984;26:99-102.
31. Herman JB, Medalie JH, Goldbourt U. Differences in cardiovascular morbidity and mortality between previously known and newly diagnosed adult diabetics. Diabetologia. 1977;13:229-234.
32. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin dependent diabetes. Circulation. 1993;88:1421-1430.
33. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in the elderly subjects. Diabetes. 1994;43:960-967.
34. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 years. Diabetes. 1987;36:179-186.
35. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body fat distribution. Diabetes. 1990;39:283-288.
36. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. Association of elevated fasting C-peptide level and increased intraabdominal fat distribution with development of type II diabetes in Japanese-American men. Diabetes. 1990;39:104-111.
37. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white populations: Paris Prospective Study. Diabetes. 1991;40:796-769.
38. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk factors as predictors of type II (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36:553-559.
39. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
40. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. Prospective studies of Pima Indians. NEJM. 1993;329:1988-1992.
41. Klein R. Kelly West Lecture 1994. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
42. Jensen-Urstad JK, Reichard PG, Rosfors JS, Lindblad LEL, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes. 1996;45:1253-1258.
43. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 1995;15:431-440.
44. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin dependent diabetes mellitus in a community of older adults. Am J Epidemiol. 1990;131:443-453.
45. Medalie JH, Papier CM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10,000 men. Arch Int Med. 1975;135:811-817.
46. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
47. Stern MP. Do non-insulin dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med. 1996;124:110-106.
48. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154-160.
49. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive during 91/2 year follow-up of the Helsinki Policeman Study population. Acta Med Scand. 1985;701(Suppl):38-52.
50. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study 10 years later. Horm Metab Res. 1985;15(Suppl)41-46.
51. Després JP, Lamarche B, Mauriége P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. NEJM. 1996;334:952-957.
52. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA. Insulin as a predictor of coronary heart disease: interaction with Apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol. 1994;4:40-45.
53. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia. 1992;35:766-770.
54. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol. 1994;140:857-869.
55. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapää P. Asymptomatic atherosclerosis and insulin resistance. Arteriosclerosis and Thrombosis. 1991;11:1068-1076.
56. Bressler P, Bailey S, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996;39:1345-1350.
57. Howard G, O'Leary DH, Zaccaro D, Haffner SM, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
58. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Verme D. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes. 1996;45:736-741.
59. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkänen L, Selby J, Howard G, Savage PJ, Hamman RF, Wagenknecht LE, Bergman RN. Increased insulin resistance and insulin secretion in non-diabetic African Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45:742-748.
60. Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11 year follow-up of the Paris Prospective Study. Diabetologia. 32:300-304.
61. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-825.
62. Pyörälä K, Pedersen JR, Kjekshus J, Faergerman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
63. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA. 1993;269:3015-3023.
64. Miettinen H, Lehto S, Salomaa W, Mähönen M, Miemalä M, Haffner SM, Pyörälä K, Tuomilehto J. Higher mortality after mayocardial infarction in diabetic than in non-diabetic patients. Diabetes Care, (in press).
65. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA. 1990;264:723-726.
66. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. NEJM. 1988;318:81-86.
67. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by Atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
68. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, Atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
69. Agardh CD, Nilsson-Ehle P, Scherstén B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care. 1982;5:322-325.
70. Taskinen MR, Beltz WF, Harper I, Fields RM, Schonfeld G, Grundy SM, Howard BV. Effects of NIDDM on very low density lipoprotein triglyceride and apolipoprotein B metabolism: studies before and after sulfonylurea therapy. Diabetes. 1986;35:1268-1277.
71. Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes. Horm Metab Res. 1985;15(Suppl):46-51.
72. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl 2):789-830.
73. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Johnson-Nagel N, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS for the VA CSDM group. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Diabetes Care. 1995;18:1113-1123.
74. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on glycemic control and complications in NIDDM. Ann Intern Med. 1996;124:131-135.
75. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS and the Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM) group. Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes. Arch Intern Med. 1997;157:181-188.
76. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
77. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993; 329:977-986.
78. Stout RW. Insulin and atheroma: 20-year perspective. Diabetes Care. 1990;13:631-654.
79. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 1993;16:1517-1520.
80. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia. 1983;24:404-411.
81. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetologia. 1994;37:945-947.
82. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia. 1994;37:948-952.
83. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia. 37:953-955.
84. Stern MP. The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia. 1994;37:956-958.
85. Haffner SM, Howard G, Mayer E, Brgman RN, Savage PJ, Rewers M, Mykkänen L, Karter AJ, Hamman R, Saad MF. Insulin sensitivity and acute insulin response in African-American, non-Hispanic whites, and Hispanics with NIDDM. The Insulin Resistance Atherosclerosis Study. Diabetes. 1997;46:63-69.
86. Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 1989;38:784-792.
87. Chaiken RC, Banerji MA, Pasmantier R, Huey H, Hirsch S, Lebovitz HE. Patterns of glucose and lipid abnormalities in black NIDDM subjects. Diabetes Care. 1991;14:1036-1042.
88. D'Agostino R, Jr., Haffner S. Insulin resistance is associated with more atherogenic cardiovascular risk factors in diabetes. Presented at the 1996 EASD meeting. September, 1996. Vienna, Austria. Diabetologia. 1996; 39(Suppl 1):A278.
89. Lebovitz HE. Oral antidiabetic agents: the emergence of alpha-glucosidase inhibitors. Drugs. 1992;44(Suppl 3):21-28.
90. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
91. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1995;18:1510-1518.
92. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala P, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. NEJM. 1992;327:1426-1433.
93. DeFronzo RA, Goodman AM for the Multicenter Metformin Study Group. Efficacy of Metformin in patients with non-insulin dependent diabetes mellitus. NEJM. 1995;333:541-549.
94. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM. The efficacy of acarbose in treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med. 1994;121:928-935.
95. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
96. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with Troglitazone. NEJM. 1994;331:1188-1193.
97. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma V, Shigeta Y, Kaneko T. Effects of Troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19: 151-156.
98. Keen H. Insulin resistance and the prevention of diabetes mellitus. NEJM. 1994;331:1226-1227.
99. Drury PL. Diabetes and arterial hypertension. Diabetologia. 1983;24:1-9.
100. Bengtsson C, Blohme G, Lapidus L, Lindquist O, Lundgren H, Nystrom E, et al. Do antihypertensive drugs precipitate diabetes? BMJ. 1984;289:1495-1497.
101. Bengtsson C, Blohme G, Lapidus L, Lundgren H. Diabetes in hypertensive women: an effect of antihypertensive drugs or the hypertensive state per se? Diabet Med. 1988;5:261-24.
102. Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ. 298:1147-1152.
103. Morales PA, Mitchell BD, Valdez RA, Hazuda HP, Stern MP, Haffner SM. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects: the San Antonio Heart Study. Diabetes. 1993;42:154-161.
104. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M, Haffner SM. Increased risk of non-insulin dependent diabetes mellitus in elderly hypertensive subjects. J Hypertension. 1994;12:1425-1432.
105. Lithell H. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
106. Gurwitz JH, Bohn RJ, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1993;118:273-278.